$APRE
Aprea Therapeutics, Inc.
CIK:0001781983|SEC Filings
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||
| Grant revenue | $ 118,111 | $ 280,574 | ||
| Operating expenses: | ||||
| Research and development | $ 2,462,042 | 1,912,213 | $ 4,073,209 | 4,395,279 |
| General and administrative | 1,570,138 | 1,593,671 | 3,389,383 | 3,358,650 |
| Total operating expenses | 4,032,180 | 3,505,884 | 7,462,592 | 7,753,929 |
| Loss from operations | (4,032,180) | (3,387,773) | (7,462,592) | (7,473,355) |
| Other income (expense): | ||||
| Interest income | 358,923 | 178,027 | 493,707 | 382,753 |
| Other income | 79,000 | 79,000 | ||
| Foreign currency gain (loss) | 2,953 | (29,124) | 10,664 | (80,927) |
| Total other income | 440,876 | 148,903 | 583,371 | 301,826 |
| Net loss | (3,591,304) | (3,238,870) | (6,879,221) | (7,171,529) |
| Other comprehensive income: | ||||
| Foreign currency translation | 8,083 | (1,681) | 17,097 | (1,038) |
| Total comprehensive loss | $ (3,583,221) | $ (3,240,551) | $ (6,862,124) | $ (7,172,567) |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | $ (0.07) | $ (0.53) | $ (0.2) | $ (1.19) |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (0.07) | $ (0.53) | $ (0.2) | $ (1.19) |
| Weighted-average common shares outstanding, basic (in shares) | 53,483,504 | 6,083,329 | 34,191,653 | 6,038,845 |
| Weighted-average common shares outstanding, diluted (in shares) | 53,483,504 | 6,083,329 | 34,191,653 | 6,038,845 |